Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

316 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.
Kok PS, Forde PM, Hughes B, Sun Z, Brown C, Ramalingam S, Cook A, Lesterhuis WJ, Yip S, O'Byrne K, Pavlakis N, Brahmer J, Anagnostou V, Ford K, Fitzpatrick K, Bricker A, Cummins MM, Stockler M, Nowak AK; Thoracic Oncology Group of Australasia (TOGA) and PrECOG, USA. Kok PS, et al. Among authors: pavlakis n. BMJ Open. 2022 Jan 25;12(1):e057663. doi: 10.1136/bmjopen-2021-057663. BMJ Open. 2022. PMID: 35078853 Free PMC article.
Bisphosphonates for breast cancer.
Pavlakis N, Stockler M. Pavlakis N, et al. Cochrane Database Syst Rev. 2002;(1):CD003474. doi: 10.1002/14651858.CD003474. Cochrane Database Syst Rev. 2002. PMID: 11869664 Updated. Review.
Bisphosphonates for breast cancer.
Pavlakis N, Schmidt R, Stockler M. Pavlakis N, et al. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. doi: 10.1002/14651858.CD003474.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034900 Updated. Review.
Bisphosphonates and other bone agents for breast cancer.
Wong MH, Stockler MR, Pavlakis N. Wong MH, et al. Among authors: pavlakis n. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD003474. doi: 10.1002/14651858.CD003474.pub3. Cochrane Database Syst Rev. 2012. PMID: 22336790 Updated. Review.
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
Buikhuisen WA, Burgers JA, Vincent AD, Korse CM, van Klaveren RJ, Schramel FM, Pavlakis N, Nowak AK, Custers FL, Schouwink JH, Gans SJ, Groen HJ, Strankinga WF, Baas P. Buikhuisen WA, et al. Among authors: pavlakis n. Lancet Oncol. 2013 May;14(6):543-51. doi: 10.1016/S1470-2045(13)70125-6. Epub 2013 Apr 12. Lancet Oncol. 2013. PMID: 23583604 Clinical Trial.
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
Nowak AK, Brown C, Millward MJ, Creaney J, Byrne MJ, Hughes B, Kremmidiotis G, Bibby DC, Leske AF, Mitchell PLR, Pavlakis N, Boyer M, Stockler MR. Nowak AK, et al. Among authors: pavlakis n. Lung Cancer. 2013 Sep;81(3):422-427. doi: 10.1016/j.lungcan.2013.05.006. Epub 2013 Jun 17. Lung Cancer. 2013. PMID: 23787063 Clinical Trial.
316 results